Skip to content

Summit Therapeutics

US · SMMT #1207 by market cap Listed 2015
9.95 -0.62 -5.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Quant vs Street three independent views, side by side

StockVane factor grade
D+
Momentum strategy signal
Strong Sell
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

✦ Quant Analyst Revision Trend how this is computed

Improving
3 1
■ Upgrades■ Downgrades
  • 3 upgrades vs 1 downgrade among tracked analyst rating changes.
  • Most recent: Leerink Partners moved from Sell to Hold on 2026-11-18.

Analyst consensus 13 analysts

Buy
Avg price target 27.57 +177.1%
Price target rangecurrent 9.95
Low8.30
Avg27.57
High43.00
Buy 62% Hold 31% Sell 8%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-19 Leerink Partners -- Hold 11.00
2026-11-18 Bernstein -- Sell 8.30
2026-11-18 Leerink Partners -- Hold --
2026-11-17 H.C. Wainwright -- Hold --
2026-11-16 Piper Sandler -- Hold 16.00
2026-11-16 Stifel -- Buy 37.00
2026-11-16 Citi -- Buy 42.00
2026-11-16 H.C. Wainwright -- Hold --
2026-11-16 Barclays -- Hold 18.00
2026-11-15 Wells Fargo -- Buy 30.00
2026-11-15 Citi -- Buy 42.00
2026-11-15 Goldman Sachs -- Buy 43.00
2026-11-11 Wells Fargo -- Buy 30.00
2026-11-05 Evercore -- Buy 34.00
2026-11-05 Stifel -- Buy 37.00
2026-11-05 Citi -- Buy 43.00
2026-11-05 H.C. Wainwright -- Hold --
2026-11-04 Goldman Sachs -- Buy 43.00
2026-11-04 Barclays -- Hold 20.00
2026-11-02 H.C. Wainwright -- Hold --
2026-10-27 H.C. Wainwright -- Hold --
2026-10-26 UBS -- Buy 33.00
2026-10-26 Citi -- Buy 43.00
2026-10-25 Goldman Sachs -- Buy 43.00
2026-10-23 H.C. Wainwright -- Hold --

Price target trend monthly average, last 3 years

Recent rating changes

DateFirmChangeTarget
2026-11-18 Leerink Partners Sell → Hold --
2026-09-09 Jefferies Hold → Buy 25.00
2026-05-22 H.C. Wainwright Buy → Hold --
2025-12-17 Barclays Sell → Hold 18.00

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-04 After close ±8.99% -12.24% (beat)
2026/Q2 2026-07-23 After close ±16.02% -8.81% (in line)
2025/Q4 2026-02-23 After close ±9.35% +0.19% (in line)
2025/Q3 2025-10-20 -- ±21.61% -4.55% (in line)
2025/Q1 2025-05-01 After close ±12.42% +13.09% (beat)
2024/Q4 2025-02-24 -- ±14.52% -14.83% (beat)
2024/Q3 2024-10-30 -- ±9.81% -14.57% (beat)
2024/Q2 2024-08-06 -- ±15.76% -4.74% (in line)
2024/Q1 2024-05-01 -- ±26.01% +19.59% (in line)
2023/Q4 2024-02-20 -- ±22.19% -26.23% (beat)
2023/Q3 2023-11-07 -- ±31.74% -12.16% (in line)
2023/Q2 2023-08-09 -- ±19.66% +10.86% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.

Summit Therapeutics discussion 0 comments

Add a comment